Tagrisso contains osimertinib, an oral targeted anticancer medicine classified as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is used in specific treatment settings for non-small cell lung cancer (NSCLC) associated with particular EGFR mutations.
The clinical role of osimertinib depends on the cancer’s molecular characteristics, disease stage, previous treatment and the patient’s overall medical condition. Depending on the applicable product authorization, it may be used after complete surgical removal of a tumor, following certain chemoradiation treatment, or for locally advanced or metastatic disease. In selected settings, it may be prescribed with pemetrexed and platinum-based chemotherapy.
Treatment selection requires clinical assessment and appropriate molecular testing. A diagnosis of lung cancer alone does not establish eligibility for osimertinib. The treating oncology team must determine whether the patient meets the requirements for the intended treatment indication.
Pharmacological Classification
Osimertinib belongs to the targeted therapy class known as EGFR tyrosine kinase inhibitors. EGFR is a receptor protein involved in transmitting signals that regulate cell growth, division and survival.
Certain EGFR mutations can cause abnormal signaling that contributes to cancer development and progression. Osimertinib inhibits susceptible mutant forms of EGFR, including specified activating mutations such as exon 19 deletions and the exon 21 L858R substitution. It also has activity against the T790M resistance mutation.
This activity helps explain why osimertinib is used in molecularly selected lung cancer treatment settings. It does not mean that the medicine will work against every EGFR alteration or every type of lung cancer.
EGFR Mutation Testing
Molecular testing is an important part of determining whether osimertinib may be appropriate. The test identifies genetic alterations in the tumor that may be relevant to targeted treatment.
Testing may use tumor tissue or another validated specimen, depending on the clinical situation and the method used. The result must be interpreted alongside the cancer diagnosis, disease stage, previous treatment and the specific indication being considered.
Different treatment settings may require different molecular criteria. A finding that supports one indication does not automatically establish eligibility for every other indication involving osimertinib.
If a result is inconclusive or does not provide sufficient information, the oncology team may consider further evaluation. Patients should not independently interpret a molecular report or select treatment based solely on a general website explanation.
Clinical Uses of Tagrisso
The following treatment settings are established uses in applicable product information, but availability and eligibility criteria can vary by jurisdiction.
Adjuvant Treatment After Surgery
Tagrisso may be used in eligible adults with EGFR-mutated NSCLC after complete surgical removal of the tumor. This is called adjuvant treatment. The objective is to reduce the risk of the cancer returning after surgery.
The decision depends on the tumor’s molecular characteristics, disease stage, previous treatment and the patient’s clinical circumstances. The oncology team determines whether adjuvant treatment is appropriate and establishes the treatment and follow-up plan.
Locally Advanced NSCLC Following Chemoradiation
For selected adults with unresectable stage III NSCLC carrying specified EGFR mutations, osimertinib may be used after platinum-based chemoradiation when the disease has not progressed during or following that treatment.
This setting has specific eligibility criteria and should not be confused with the treatment of every stage III lung cancer. The applicable prescribing information and clinical history must be reviewed before treatment is selected.
Initial Treatment of Advanced or Metastatic NSCLC
Osimertinib may be prescribed as initial targeted treatment for eligible patients with locally advanced or metastatic NSCLC carrying specified activating EGFR mutations.
The treatment aims to inhibit abnormal EGFR signaling associated with the tumor. The oncology team evaluates the patient’s molecular results, disease extent, overall condition and treatment preferences when developing a plan.
Treatment of T790M-Positive Disease
In certain settings, osimertinib may be used for metastatic NSCLC carrying the EGFR T790M resistance mutation after progression during or following previous EGFR tyrosine kinase inhibitor treatment.
T790M is relevant because it can contribute to resistance to certain earlier targeted medicines. The appropriate treatment decision depends on the test result, previous therapy and applicable product authorization.
Combination With Chemotherapy
In selected patients with locally advanced or metastatic NSCLC carrying specified activating EGFR mutations, Tagrisso may be used with pemetrexed and platinum-based chemotherapy.
Combination treatment introduces additional medicines, each with its own adverse effects and administration requirements. The oncology team must determine whether the combination is appropriate and explain the expected benefits, risks and monitoring needs.
Mechanism of Action
EGFR normally participates in signaling pathways that regulate cellular activity. When certain mutations make the receptor abnormally active, cancer cells may receive persistent signals supporting growth and survival.
Osimertinib inhibits susceptible mutant forms of EGFR by blocking their tyrosine kinase activity. This interferes with signaling pathways that contribute to cancer-cell growth.
Its activity against specific activating mutations and the T790M resistance mutation supports its use in defined clinical settings. However, tumor biology can change over time, and cancer may become resistant to treatment. Continued clinical assessment is therefore necessary.
The medicine’s targeted action does not eliminate the possibility of adverse effects. EGFR-related pathways also have functions in healthy tissues, and osimertinib can affect organs such as the lungs, heart and eyes.
General Dosage and Administration
The usual adult regimen described in official prescribing information is 80 mg orally once daily. The exact regimen and any modifications must follow the applicable prescribing information and the treating clinician’s instructions.
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Patients should not independently change the dose, take extra tablets after a missed dose or discontinue treatment because of suspected adverse effects. If a dose is missed, the patient should follow the official patient leaflet or contact the oncology team for guidance.
Food and administration instructions should also be confirmed against the current official patient information for the product being used.
Patient Monitoring
Monitoring helps the healthcare team evaluate treatment tolerance, identify complications and assess the ongoing response to treatment.
Depending on the patient’s condition, the monitoring plan may include:
- Clinical assessment: Review of symptoms, general health and functional status.
- Pulmonary assessment: Evaluation of new or worsening cough, breathing difficulties or other symptoms that may suggest lung inflammation.
- Cardiac assessment: Review of heart-related symptoms and risk factors, with electrocardiography or other investigations when indicated.
- Laboratory evaluation: Blood tests or electrolyte assessments when required by the clinical situation and prescribing information.
- Eye assessment: Evaluation of significant eye pain, irritation or visual changes.
- Medication review: Assessment of concurrent medicines, supplements and possible interactions.
- Cancer response assessment: Appropriate imaging and clinical evaluation to determine how the disease is responding.
The exact monitoring schedule should be individualized. Not every patient will require every investigation at the same frequency.
Important Clinical Warnings
Osimertinib can cause serious adverse reactions, including interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
New or worsening breathing difficulties, persistent cough, fainting, a rapid or irregular heartbeat, chest symptoms, significant eye pain or changes in vision require prompt medical assessment. Severe or rapidly worsening symptoms may require emergency care.
If a serious adverse reaction is suspected, the healthcare team determines whether treatment interruption, additional testing or another intervention is necessary. Patients should not make these decisions independently.
Drug Interactions and Medical History
Before treatment, patients should provide their healthcare team with a complete list of medicines, vitamins, supplements and herbal products they use. Certain combinations may increase risks or require additional precautions.
The oncology team should also be informed about existing heart conditions, lung disease, eye problems, previous serious medicine reactions and other relevant medical conditions.
Pregnancy, contraception and breastfeeding require specific discussion before treatment. Patients should follow the applicable prescribing information and individualized medical advice.
Clinical Role and Treatment Expectations
Tagrisso is a targeted treatment for selected molecularly defined lung cancer settings. Its purpose and expected benefits depend on whether it is being used after surgery, following chemoradiation or for advanced disease.
No treatment outcome can be guaranteed. Some patients may experience meaningful disease control, while others may have limited benefit or develop resistance. The treating team explains the treatment objectives and determines how the response should be assessed.
Conclusion
Clinical use of Tagrisso requires appropriate molecular testing, careful selection of the treatment setting, review of medical history and ongoing monitoring. The medicine has important benefits for eligible patients but also carries potentially serious risks.
Patients should discuss their test results, treatment options, administration instructions and symptoms with a qualified oncology professional.
Medical Disclaimer: This page is for educational and informational purposes only. It does not replace professional medical advice, diagnosis, treatment or official prescribing information. Do not start, stop or change a prescription medicine based solely on website content. Seek immediate local emergency assistance for a medical emergency.